Obesity is one of the most prominent risk factors for the development and progression of osteoarthritis in the lower limb, especially in the knee ([@CIT0013], [@CIT0043]). As a result, overweight people are overrepresented among patients undergoing joint replacement surgery ([@CIT0007], [@CIT0008], [@CIT0026], [@CIT0024]). With an increasing proportion of elderly people and the high prevalence of overweight/obesity in the general population, the demand for joint replacement surgery is expected to rise ([@CIT0030]). Considerable risks of peroperative and postoperative complications have been reported for obese patients undergoing hip or knee replacement surgery ([@CIT0045], [@CIT0016], [@CIT0039]), although with conflicting results ([@CIT0036], [@CIT0020], [@CIT0022], [@CIT0045], [@CIT0042], [@CIT0016], [@CIT0017], [@CIT0014], [@CIT0009]). The majority of previous studies have focused on orthopedic-related outcomes, e.g. risks of infection and prosthesis dislocation ([@CIT0041], [@CIT0020], [@CIT0010], [@CIT0001], [@CIT0021]). Major surgical procedures, including joint replacement surgery, also carry a significant risk of adverse cardiovascular events and mortality. Previous research has suggested that obesity may increase perioperative cardiovascular and mortality risks, but it has not concentrated specifically on elective hip and knee replacement surgery ([@CIT0005]). We therefore evaluated the relationship between body mass index (BMI) and perioperative cardiovascular events and mortality, as well as 1-year mortality, in patients undergoing elective total hip or knee replacement in a nationwide setting. We hypothesized that obese patients would have higher risk of adverse cardiovascular events than patients who were not obese.

Methods {#ss1}
=======

In Denmark (with 5.5 million citizens), medical care is tax-financed, free of charge to private individuals, and available to all. For administrative purposes, the government has kept records on several healthcare-related variables, which were used for the present study.

From the Danish National Patient Register and the Danish Anesthesia Register, we identified patients who had undergone elective primary hip and knee replacement surgery between 2005 and 2011. Data on admission dates, operation dates, discharge dates, and diagnoses were available in these registers. Diagnoses were coded according to the international classification system (ICD tenth revision: ICD-10) and surgical procedures were coded according to a national classification system for surgeries (NOMESKO NCPS). When defining comorbidities, we considered validated in-hospital discharge codes up to 5 years before surgery ([@CIT0044]). However, to minimize the risk of confounding, discharge codes from in-hospital stays and also outpatient clinics at any point prior to surgery (back until 1994 when the ICD-10 system was introduced) were considered for rheumatoid arthritis (ICD-10 codes M05--06), as these patients were excluded from analysis.

Information on vital status, date of birth, and sex was collected from the National Population Register and information on causes of deaths was obtained from the National Causes of Death Register. Information on smoking, alcohol consumption, American Society of Anesthesiology (ASA) risk score, and BMI was retrieved from the Danish Anesthesia Register. BMI was calculated from self-reported and/or measured weight and height registered for all patients before surgery. Patients were classified according to the definitions of the World Health Organization (WHO), as underweight (BMI \< 18.5 kg/m^2^), normal weight (18.5--24 kg/m^2^), overweight (25--29 kg/m^2^), obese 1 (30--34 kg/m^2^), or obese 2 (≥ 35 kg/m^2^).

Pharmacological treatment prior to surgery was identified from the Danish Register of Medicinal Product Statistics, where all prescriptions claimed have been registered since 1995. In accordance with previous work ([@CIT0038], [@CIT0003]), diabetes was defined by a claimed prescription being registered for glucose-lowering medication in the 120 days before the index date. Treatment with vitamin K antagonists, aspirin, clopidogrel, beta-blockers, calcium channel blockers, angiotensin-converting enzyme/angiotensin II (ACE) inhibitors, and aldosterone blockers was defined by the same method and using the same time window (120 days) ([@CIT0004]). Severity of heart failure was estimated using loop diuretic dosages, as described previously ([@CIT0002]).

Study population {#ss2}
----------------

We identified all patients aged ≥ 20 years who had undergone elective primary hip or knee replacement (NOMESKO NCPS codes KNGB20--40 (knee) or KNFB20--40 (hip)) between 2005 and 2011. We discriminated between cemented prostheses (KNGB30--40, KNFB30--40) and uncemented prostheses (KNGB20, KNFB20). To create as homogenous a population as possible, we excluded patients with rheumatoid arthritis (ICD-10 codes M05--06) or a hip/knee fracture within 30 days prior to surgery (ICD-10 code DS72 (hip surgery) and DS82 (knee surgery)). In total 34,744 patients were included, almost half of whom received a total knee replacement (45%). Altogether, 1.0% of patients were classified as underweight, 28% as normal weight, 40% as overweight, 21% as obese 1, and 10% as obese 2 ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                    Underweight\        Normal weight\      Overweight\         Obese 1\            Obese 2\
                                                                    n = 353             n = 9,859           n = 13,787          n = 7,450           n = 3,295
  ----------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Body mass index, kg/m^2^ [**^a^**](#T1-F1){ref-type="table-fn"}   17.6 (14.1--18.5)   23.3 (18.5--25.0)   27.4 (25.0--30.0)   31.9 (30.0--35.0)   37.6 (35.0--50.0)

  Age, years [**^b^**](#T1-F2){ref-type="table-fn"}                 75 (65--82)         75 (65--82)         71 (64--78)         67 (62--74)         65 (59--71)

  Sex, male                                                         33 (9%)             3,382 (34%)         6,625 (48%)         3,153 (42%)         1,113 (34%)

  Total hip replacement                                             307 (87%)           6,676 (68%)         7,765 (56%)         3,250 (44%)         1,130 (34%)

  Surgery time, min                                                 70 (55--90)         70 (55--87)         70 (55--89)         75 (60--93)         80 (65--100)

  ASA score 1                                                       68 (19%)            3,081 (31%)         3,610 (26%)         1,272 (17%)         236 (7%)

  ASA score 2                                                       208 (59%)           5,586 (57%)         8,532 (62%)         5,052 (68%)         2,042 (62%)

  ASA score 3+                                                      68 (19%)            1,061 (11%)         1,491 (11%)         1,044 (14%)         980 (30%)

  Heart failure                                                     8 (3%)              196 (2%)            287 (2%)            185 (2%)            86 (3%)

  Current smoker                                                    119 (33%)           1,786 (18%)         2,059 (15%)         1,033 (14%)         446 (14%)

  Cerebrovascular disease                                           18 (14%)            311 (3%)            351 3%)             185 (2%)            78 (2%)

  COPD                                                              24 (7%)             233 (2%)            264 (2%)            171 (2%)            113 (3%)

  Anemia                                                            19 (5%)             266 (3%)            229 (2%)            108 (1.4%)          60 (2%)

  Renal disease                                                     3 (0.8%)            78 (0.8%)           90 (0.7%)           58 (0.8%)           29 (0.9%)

  Peripheral artery disease                                         5 (1%)              63 (0.6%)           74 (0.5%)           46 (0.6%)           25 (0.8%)

  Acute myocardial infarction                                       7 (2%)              155 (2%)            242 (2%)            146 (2%)            51 (2%)

  Atrial fibrillation                                               21 (6%)             444 (5%)            605 (4%)            342 (5%)            152 (5%)

  Statin treatment                                                  51 (14%)            1,835 (19%)         3,454 (25%)         2,256 (30%)         961 (29%)

  Diabetes                                                          10 (3%)             360 (4%)            943 (6.8%)          907 (12%)           607 (18%)

  Calcium channel blockers                                          40 (11%)            1,618 (16%)         2,636 (19%)         1,765 (24%)         742 (23%)

  ACE inhibitors                                                    76 (22%)            2,416 (25%)         4,398 (32%)         3,114 (42%)         1,542 (47%)

  Thiazides                                                         44 (12%)            1,359 (14%)         2,512 (18%)         1,563 (21%)         808 (25%)

  Aldosterone blockers [**^c^**](#T1-F3){ref-type="table-fn"}       14 (4%)             142 (1%)            237 (2%)            181 (2%)            112 (3%)

  Clopidogrel                                                       4 (1%)              114 (1%)            170 (1%)            107 (1%)            24 (0.7%)

  Beta blocker                                                      39 (11%)            1,277 (13%)         2,336 (17%)         1,525 (20%)         727 (22%)

  Vitamin K antagonists                                             15 (4%)             413 (4%)            642 (5%)            352 (5%)            166 (5%)

  Aspirin                                                           56 (16%)            1,839 (19%)         2,912 (21%)         1,743 (23%)         763 (23%)

  Alcohol, 0 drinks/week                                            160 (45%)           3,649 (37%)         4,927 (36%)         2,981 (40%)         1,582 (48%)

  Alcohol, 1--14 drinks/week                                        107 (30%)           3,791 (38%)         5,259 (38%)         2,639 (35%)         948 (29%)

  Alcohol, 15--21 drinks/week                                       16 (5%)             499 (5%)            903 (7%)            403 (5%)            127 (4%)

  Alcohol, \> 21 drinks/week                                        23 (7%)             616 (6%)            962 (7%)            516 (7%)            228 (7%)

  Alcohol, unknown                                                  47 (13%)            1,304 (13%)         1,734 (13%)         911 (12%)           410 (12%)

  No loop diuretics (%)                                             319 (90%)           9,255 (94%)         12,793 (93%)        6,606 (89%)         2,713 (82%)

  Loop diuretics ≤ 40 mg/day                                        17 (5%)             346 (4%)            559 (4%)            446 (6%)            293 (9%)

  Loop diuretics 41--80 mg/day                                      10 (3%)             146 (2%)            246 (2%)            230 (3%)            150 (5%)

  Loop diuretics 81--160 mg/day                                     7 (2%)              43 (0.4%)           76 (0.6%)           87 (1%)             62 (2%)

  Loop diuretics \> 160 mg/day                                      0 (0%)              69 (0.7%)           113 (0.8%)          81 (1%)             77 (2%)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

presented as median (min--max)

presented as median (interquartile range).

e.g. spironolactone

Outcome measures {#ss3}
----------------

The main outcome measures were 30-day risk of MACE (non-fatal acute myocardial infarction (ICD-10 code I21), non-fatal ischemic stroke (ICD-10 code I63--64; I64 refers to unspecified stroke, but previous data have demonstrated that the majority of these strokes are of ischemic type) ([@CIT0029]) or cardiovascular mortality (ICD-10 codes I00--I99)), and all-cause mortality. Secondary endpoints were 1-year risk of all-cause mortality and cardiovascular mortality.

Ethics {#ss4}
------

The study was approved by the Danish Data Protection Agency. In Denmark, retrospective registry-based studies do not need ethical approval.

Statistics {#ss5}
----------

We calculated hazard ratios with 95% confidence intervals (CIs) by multivariable Cox-proportional regression analyses in 4 steps to assess the relationship between BMI and risk of MACE and that between BMI and risk of mortality. In the first step, age, sex, and type of surgery (hip or knee replacement surgery) were included as covariates. In the second step, heart failure, previous myocardial infarction, chronic ischemic heart disease, atrial fibrillation, peripheral artery disease, cerebrovascular disease, chronic obstructive pulmonary disease, and renal disease were added to the model. The third model was as for the second, but it was additionally adjusted for diabetes. The fourth model was as for the third, but it was additionally adjusted for cemented vs. non-cemented prosthesis. Decision to include these variables was based on guidance from directed acyclic graphs ([@CIT0040]). The overweight group was used as the reference for all analyses (quantitatively, this group was the largest).

Unless otherwise indicated, models assumptions were tested and fulfilled (proportional hazard assumption was tested with log(-log(survival)) vs. log(time) plots; linearity of continuous variables assumption was tested by inclusion of an additional categorical variable; and no interactions assumption was tested by inclusion of an interaction term in the overall model). Dose-response graphs (adjusted for age, sex, and hip or knee replacement surgery) were created using restricted cubic spline functions by the SAS macro developed by [@CIT0011]. Knots were placed at p25, p50, and p75 for 30-day outcome measures and at p10, p25, p50, p75, and p90 for one-year outcome measures. Test for non-linearity was done with the chi-square test. There were complete data on all variables included in the analyses. A 2-sided p-value of \< 0.05 was considered significant for all statistical tests. All statistical analyses were performed with SAS version 9.2.

Results {#ss6}
=======

232 patients (0.7%) experienced a MACE within 30 days after surgery. During the same period, 111 patients (0.3%) died---74 of them (0.2%) from cardiovascular causes. The 1-year mortality figure was 582 (1.7%); 265 of these deaths (0.8%) were from cardiovascular causes. Adverse events were more common in underweight patients than in the other groups ([Table 2](#T2){ref-type="table"}).

###### 

Crude numbers of events and adjusted hazard ratios associated with different BMI groups for the individual endpoints

                                 30-day MACE         30-day mortality   30-day CV mortality   1-year mortality    1-year CV mortality
  ------------------------------ ------------------- ------------------ --------------------- ------------------- ---------------------
  *Numbers events*                                                                                                
  Underweight                    4/353 (1.1%)        6/353 (1.7%)       2/353 (0.6%)          31/353 (8.8%)       6/353 (1.7%)
  Normal weight                  78/9,859 (0.8%)     46/9,859 (0.5%)    31/9,859 (0.3%)       229/9,859 (2.3%)    104/9,859 (1.1%)
  Overweight                     77/13,787 (0.6%)    29/13,787 (0.2%)   18/13,787 (0.1%)      183/13,787 (1.3%)   83/13,787 (0.6%)
  Obese 1                        59/7,450 (0.8%)     21/7,450 (0.3%)    17/7,450 (0.2%)       95/7,450 (1.3%)     49/7,450 (0.7%)
  Obese 2                        14/3,295 (0.4%)     9/3,295 (0.3%)     6/3,295 (0.2%)        44/3,295 (1.3%)     23/3,295 (0.7%)
                                 Hazard ratio        Hazard ratio       Hazard ratio          Hazard ratio        Hazard ratio
  *Model 1 (ref = overweight)*                                                                                    
  Underweight                    2.0 (0.7--5.4)      7.7 (3.1--19)      4.1 (0.9--18)         5.7 (3.8--8.4)      2.5 (1.09--5.9)
  Normal weight                  1.3 (0.94--1.8)     2.0 (1.2--3.1)     2.07 (1.1--3.8)       1.6 (1.3--1.9)      1.5 (1.1--2.06)
  Obese 1                        1.7 (1.2--2.4)      1.6 (0.93--2.9)    2.1 (1.08--4.1)       1.2 (0.9--1.5)      1.4 (0.97--2.0)
  Obese 2                        1.2 (0.67--2.1)     2.3 (1.08--5.0)    2.4 (0.94--6.2)       1.7 (1.2--2.4)      2.2 (1.4--3.5)
  *Model 2 (ref = overweight)*                                                                                    
  Underweight                    1.6 (0.58--4.4)     7.05 (2.8--18)     3.7 (0.83--17)        5.2 (3.5--7.7)      2.3 (0.99--5.3)
  Normal weight                  1.3 (0.93--1.8)     1.9 (1.2--3.1)     2.02 (1.1--3.7)       1.6 (1.3--1.9)      1.6 (1.2--2.1)
  Obese 1                        1.6 (1.1--2.3)      1.6 (0.9--2.8)     2.0 (1.01--3.9)       1.2 (0.89--1.5)     1.3 (0.9--1.9)
  Obese 2                        1.1 (0.62--2.0)     2.07 (0.96--4.4)   2.1 (0.82--5.4)       1.5 (1.09--2.1)     1.9 (1.2--3.03)
  *Model 3 (ref = overweight)*                                                                                    
  Underweight                    1.6 (0.58--4.5)     7.2 (2.9--18)      3.8 (0.84--17)        5.3 (3.6--7.9)      2.4 (1.02--5.5)
  Normal weight                  1.3 (0.95--1.8)     2.0 (1.2--3.2)     2.05 (1.1--3.7)       1.6 (1.3--2.0)      1.6 (1.2--2.2)
  Obese 1                        1.6 (1.1--2.2)      1.5 (0.87--2.7)    2.0 (1.0--3.8)        1.1 (0.87--1.4)     1.3 (0.92--1.9)
  Obese 2                        1.04 (0.58--1.9)    1.9 (0.9--4.2)     2.05 (0.8--5.3)       1.4 (1.01--2.0)     1.8 (1.1--2.9)
  *Model 4 (ref = overweight)*                                                                                    
  Underweight                    1.2 (0.44--3.3)     7.0 (2.8--15)      3.8 (0.84--17)        5.2 (3.5--7.8)      2.4 (1.03--5.6)
  Normal weight                  0.77 (0.56--1.07)   2.0 (1.2--3.2)     2.05 (1.1--3.7)       1.6 (1.3--2.0)      1.6 (1.2--2.2)
  Obese 1                        1.2 (0.84--1.7)     1.5 (0.87--2.7)    2.0 (1.0--3.8)        1.1 (0.87--1.4)     1.3 (0.92--1.9)
  Obese 2                        0.8 (0.44--1.5)     1.9 (0.9--4.2)     2.06 (0.8--5.3)       1.4 (1.01--2.0)     1.8 (1.1--2.9)

MACE: major adverse cardiovascular events (ischemic stroke, acute myocardial infarction, and cardiovascular death); CV: cardiovascular.

Model 1 was adjusted for age, gender, and hip vs. knee replacement surgery. Model 2 was additionally adjusted for heart failure, previous myocardial infarction, chronic ischemic heart disease, atrial fibrillation, peripheral artery disease, cerebrovascular disease, chronic obstructive pulmonary disease, and renal disease. Model 3 was additionally adjusted for diabetes. Model 4 was additionally adjusted for cemented vs. non-cemented prosthesis.

Age, sex, and hip vs. knee replacement-adjusted splines are presented in the [Figure](#F1){ref-type="fig"}. As can be seen, there appeared to be a U-shaped relationship between BMI and the risk of 30-day mortality (overall and CV mortality) as well as 1-year mortality risks (p-value for non-linearity \< 0.001 for all endpoints) and a suggestion of a U-shaped relationship for 30-day MACE (p-value for non-linearity = 0.08). As can be seen in the graphs, the nadir BMI was found for overweight patients (BMI around 27--28). Similar associations were found for analyses using the discrete BMI groups ([Table 2](#T2){ref-type="table"}). Compared to overweight, the hazard ratios regarding MACE from the final adjusted model were 1.2 (95% CI: 0.4--3.3), 1.3 (0.95--1.8), 1.6 (1.1--2.2), and 1.0 (0.6--1.9) for underweight, normal weight, obese 1, and obese 2. The 30-day hazard ratios regarding mortality were 7.0 (2.8--15), 2.0 (1.2--3.2), 1.5 (0.9--2.7), and 1.9 (0.9--4.2) for underweight, normal weight, obese 1, and obese 2, compared to overweight.

![Splines of hazard ratios associated with BMI levels. Analyses were adjusted for age, gender, and type of surgery (i.e. knee vs. hip replacement surgery).](ORT-85-456-g001){#F1}

Of the other variables included in the final model, high age, cardiovascular diseases, renal disease, and diabetes tended to increase risks ([Table 3](#T3){ref-type="table"}). It is notable that hip replacement was not associated with higher hazard ratios for 30-day risk of mortality or MACE, compared to knee replacement. The association between BMI category and outcomes was also not statistically significantly different for hip and for knee replacement surgery (p-values for interactions between BMI groups and hip or knee replacement surgery were 0.28, 0.47, 0.66, 0.055, and 0.14 for 30-day mortality, 30-day CV mortality, 30-day MACE, 1-year mortality, and 1-year CV mortality, respectively).

###### 

Hazard ratios associated with other variables from multivariable Cox regression models

                                         30-day mortality   30-day CV mortality   30-day MACE         1-year mortality    1-year CV mortality
  -------------------------------------- ------------------ --------------------- ------------------- ------------------- ---------------------
  Male sex                               2.2 (1.5--3.3)     2.09 (1.3--3.4)       1.8 (1.4--2.3)      1.7 (1.5--2.07)     2.02 (1.6--2.6)
  Age, per 1 year increase               1.09 (1.06--1.1)   1.09 (1.06--1.1)      1.07 (1.05--1.09)   1.07 (1.06--1.08)   1.09 (1.07--1.10)
  COPD                                   1.7 (0.84--3.6)    1.73(0.74--4.04)      1.7 (1.02--2.9)     2.4 (1.80--3.3)     1.7 (1.08--2.7)
  Renal disease                          1.6 (0.97--2.5)    1.60 (0.93--2.7)      1.4 (0.94--2.0)     1.9 (1.6--3.3)      1.9 (1.4--2.4)
  Peripheral artery disease              3.5 (1.4--8.4)     5.0 (2.0--13)         2.1 (1.04--4.2)     1.7 (0.94--2.9)     2.4 (1.2--4.6)
  Cerebrovascular disease                3.02 (1.7--5.4)    4.05 (2.1--7.7)       6.8 (4.90--9.4)     1.5 (1.1--2.2)      2.3 (1.5--3.4)
  Heart failure                          2.07 (1.03--4.2)   3.3 (1.5--7.1)        1.5 (0.87--2.5)     1.4 (1.0--2.0)      1.9 (1.3--2.9)
  Ischemic heart disease                 1.5 (0.81--4.2)    1.1 (0.53--2.4)       1.8 (1.2--2.70)     1.5 (1.1--1.9)      1.7 (1.2--2.4)
  Acute myocardial infarction            1.02 (0.39--2.7)   1.6 (0.57--4.3)       2.01 (1.2--3.4)     0.81 (0.50--1.3)    1.1 (0.63--2.0)
  Atrial fibrillation                    0.7 (0.34--1.4)    0.5 (0.19--1.3)       0.49 (0.28--0.86)   1.4 (1.09--1.9)     1.6 (1.08--2.3)
  Diabetes                               1.7 (0.97--2.9)    1.3 (0.63--2.7)       1.6 (1.08--2.3)     1.6 (1.2--2.05)     1.7 (1.2--2.4)
  Total hip vs. knee replacement         0.99 (0.64--1.6)   0.72 (0.41--1.3)      1.01 (0.75--1.4)    1.4 (1.2--1.7)      1.2 (0.89--1.6)
  Cemented vs. uncemented arthroplasty   1.3 (0.77--2.2)    0.98 (0.51--1.9)      1.3 (0.89--1.8)     1.1 (0.98--1.4)     0.96 (0.7--1.3)

Hazard ratios are derived from model 4 (see under statistics section).

Sensitivity analyses {#ss7}
--------------------

To ensure that the increased mortality risk associated with being underweight was not driven by the high prevalence of chronic obstructive pulmonary disease, a sensitivity analysis excluding these patients was performed. This yielded similar results: hazard ratio 3.53 (1.36--9.12) for 30-day mortality, 0.76 (0.19--3.11) for 30-day MACE, 1.15 (0.15--8.63) for 30-day CV mortality, 2.75 (1.77--4.25) for 1-year mortality, and 1.50 (0.65--3.45) for 1-year CV mortality associated with underweight, compared with overweight.

Discussion {#ss8}
==========

Our main finding was that there appeared to be a U-shaped relationship between the risks of MACE and mortality, with the lowest risk being seen in overweight patients (nadir BMI 27--28). Although the underweight group had rather few patients, this group was associated with the absolutely greatest mortality risk, which may warrant further attention. This was not in agreement with our main hypothesis, but it may be explained by factors such as increased comorbidity burden in this group of patients. We hypothesized that obese patients were doing worse than patients who were not obese. Indeed, analysis of BMI groups showed a tendency of increased risks associated with being obese or very obese, compared to being overweight. In analyses based on cubic spline regressions, very obese patients (with BMI exceeding 35) had an increased risk of MACE and mortality, both in the short term (30 days) and in the long term (1 year). A cubic spline analysis uses BMI as a continuous variable and is therefore more powerful than the conventional categorization of BMI into 5 categories ([@CIT0019]). The finding that the lowest risks were associated with being overweight is interesting and is in agreement with results from a recent meta-analysis based on 2.9 million individuals (in a non-surgical setting), which showed a similar U-shaped relationship between BMI and mortality, with the lowest risks associated with being overweight ([@CIT0015]). This might seem contradictory, given that maintenance of a low/normal weight leads to improvement in several cardiovascular risk factors. However, nowadays in modern western societies, the "normal" state is often to be overweight. People who are underweight or even of normal weight may therefore be different in several ways, including having a more sedentary lifestyle with low muscle mass, or suffering from chronic comorbidities such as depression, pulmonary disease, or cardiovascular diseases with low-grade inflammation, which increases cardiovascular and mortality risks ([@CIT0031]). Moreover, dementia for example is known to have a long preclinical phase with significant weight loss up to a decade before overt disease ([@CIT0028]). All these considerations may have affected our estimates as well. As seen from [Table 1](#T1){ref-type="table"}, underweight or normal-weight patients were older and had more comorbidity than overweight or obese patients. Although we adjusted the analyses for many of these characteristics, it may be that the increased risks found for these weight groups were in part caused by comorbidity burden and high age. Despite the fact that obese patients were younger and had less comorbidity than normal-weight or overweight patients, they still had higher risks. Thus, it seems unlikely that all of our results were caused by a high comorbidity burden.

It is well known that the risk of orthopedic-related complications such as poor wound healing, chronic deep infection, dislocation of the implant, and periprosthetic fractures are increased in overweight and obese patients, but substantially less data are available on cardiovascular and mortality risks associated with obesity ([@CIT0041], [@CIT0020], [@CIT0010], [@CIT0001], [@CIT0021]). [@CIT0018] evaluated the risk of myocardial infarction in a cohort of 3,471 patients undergoing elective hip and knee replacement surgery at a tertiary-care orthopedic center in Canada between 1998 and 2003. The authors reported that 1.8% suffered from perioperative myocardial infarction and showed that high BMI was a risk factor for perioperative myocardial infarction. Other studies have, however, reported substantially lower mortality and lower rates of adverse cardiovascular events in patients undergoing hip or knee replacement surgery. Using a large database of total knee replacement operations (n = 15,943) from Kaiser Permanente (Southern Califormia, USA), [@CIT0027] reported a 90-day mortality rate of 0.3% and an acute myocardial infarction rate of 0.1% in individuals undergoing primary replacement surgery. [@CIT0034] reported that in a cohort of 10,244 American patients undergoing elective primary hip or knee replacement surgery, 0.4% suffered from a perioperative myocardial infraction and 0.5% died. Other studies have found perioperative mortality and myocardial infraction rates ranging from 0.2% to 0.7%, which is more or less comparable to our findings ([@CIT0035], [@CIT0032], [@CIT0023], [@CIT0006], [@CIT0037]).

Despite the rather low overall event rates (0.7% MACE and 0.3% mortality during the first 30 days after surgery), we can, however, conclude that there is a U-shaped relationship between BMI and the risks of MACE and mortality---with the lowest risks being carried by overweight patients. Increased attention and thorough preoperative evaluation is therefore warranted for patients at the extremes of the BMI spectrum. In addition, several comorbidities such as diabetes, vascular diseases, atrial fibrillation, and kidney disease are often present in obese people, which---as also supported by our data ([Table 3](#T3){ref-type="table"})---is associated with increased risk of perioperative MACE and mortality.

Strengths and limitations {#ss9}
-------------------------

The main strength of our study was the large and representative population. The national registries we used have good specificity and positive predictive values for the diagnoses myocardial infarction and ischemic stroke ([@CIT0025], [@CIT0033]). However, as measurement of troponins and electrocardiograms were not performed routinely postoperatively, some non-fatal acute myocardial infarctions may have been missed ([@CIT0012]). The mortality associated with postoperative myocardial infarctions that are missed is, however, high and would therefore be reflected in the mortality analyses to some extent ([@CIT0012]). The numbers of events were rather small for most groups, and statistical type-2 error (i.e. failure to reject a false null hypothesis) can therefore not be excluded. Furthermore, we did not have exact indications for surgery; and although used in research previously, the validity of the Danish Anesthesia Register is unknown. BMI in particular was not obtained in a standardized way and may even have been based on self-reported weight and height measurements in some cases.

In summary, in an unselected cohort of patients who underwent elective primary hip or knee replacement surgery, there appeared to be U-shaped risks of perioperative MACE and mortality in relation to BMI. Notably, underweight and extreme obesity may help to identify patients who are at higher risk and who therefore warrant more attention.
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